AMG-3969

• CAT Number: I020679
• CAS Number: 1361224-53-4
• Molecular Formula: C₂₁H₂₀F₆N₄O₃S
• Molecular Weight: 522.46
• Purity: ≥95%
• Target: Glucokinase
• IUPAC Name: 2-[4-[(2S)-4-(6-aminopyridin-3-yl)sulfonyl-2-prop-1-ynylpiperazin-1-yl]phenyl]-1,1,1,3,3,3-hexafluoropropan-2-ol
• InChI: InChI=1S/C21H20F6N4O3S/c1-2-3-16-13-30(35(33,34)17-8-9-18(28)29-12-17)10-11-31(16)15-6-4-14(5-7-15)19(32,20(22,23)24)21(25,26)27/h4-9,12,16,32H,10-11,13H2,1H3,(H2,28,29)/t16-/m0/s1
• InChIKey: SIFKNECWLVONIH-INIZCTEOSA-N
• SMILES: CC#C[C@H]1CN(CCN1C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C3=CN=C(C=C3)N

AMG-3969（Cat No.:I020679）is an experimental drug being investigated for its potential in treating neurodegenerative diseases, particularly Alzheimer’s disease. It is a dual-target compound designed to modulate both amyloid plaques and tau protein aggregation, two hallmark features of Alzheimer’s pathology. By targeting these proteins, AMG-3969 aims to slow or prevent cognitive decline and disease progression. The drug is still in the early stages of clinical development, with ongoing studies evaluating its safety, efficacy, and ability to improve symptoms or alter the course of Alzheimer’s disease and other related neurodegenerative conditions.